Ticker: DFTX

Definium Therapeutics

Biotech Healthcare Biotechnology

Price 37.69

Reco Sell Potential 39 Risk 76 Updated 2026-09-10

Official website

Forecast impact

positive

Target +44.8% target fill 69.1%

Reaction D5 +7.79% · D10 +2.57% fresh confirmed · market trust

Impact Potential +6 · Risk -3 valid until 2026-09-13

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Definium Therapeutics is a healthcare company focused on developing innovative therapies for cancer treatment. Its core products include targeted therapies and immunotherapies aimed at specific cancer types. The company operates primarily in the biotechnology segment, with its main revenue sources stemming from research collaborations, grants, and potential future product sales. Definium is engaged in clinical trials to advance its pipeline of drug candidates.

Investment Profile

The investment profile of Definium Therapeutics is more aligned with growth investors, given its focus on developing new therapies and the potential for significant future returns. However, the high risk associated with its current financial performance and lack of revenue may deter conservative investors. The stock may appeal to those with a longer investment horizon who are willing to accept volatility in pursuit of growth opportunities.

Category: Biotech Sector: Healthcare Industry: Biotechnology Investment style: Growth Horizon: Medium-term Company type: Small Cap

Fundamental metrics (experimental) Updated: 2026-09-05

EPS (TTM) — earnings per share for the last 12 months, $: -3.44
EPS surprise: -166.2%
20d volatility: 2.8%

AI recommendation changes

Date	Before	After	Reason
2026-08-29	Hold	Sell	Weak fundamentals and negative momentum raise significant concerns.
2026-08-18	Sell	Hold	High volatility and negative earnings raise concerns.
2026-08-15	Hold	Sell	Weak fundamentals and negative momentum raise significant concerns.
2026-08-05	Sell	Hold	Weak fundamentals and high volatility raise concerns.
2026-08-04	Hold	Sell	Weak fundamentals and negative momentum raise significant concerns.
2026-07-31	Sell	Hold	High volatility and negative EPS raise concerns.
2026-07-19	Hold	Sell	Weak fundamentals and high volatility raise concerns.
2026-07-09	Sell	Hold	High volatility and negative earnings raise concerns.
2026-07-01	Hold	Sell	High volatility; uncertain fundamentals warrant caution.
2026-06-11	Sell	Hold	Weak fundamentals and high volatility raise concerns.
2026-06-01	Hold	Sell	High volatility; fundamentals show significant weakness.
2026-05-20	Sell	Hold	Weak fundamentals and negative momentum raise significant concerns.
2026-05-10	Hold	Sell	Weak fundamentals and negative momentum raise significant concerns.
2026-05-08	—	Hold	Strong momentum, but fundamentals show significant losses.
2026-05-08	Hold	Hold	Компания показывает сильный рост за последние 60 и 120 дней, что свидетельствует о положительной динамике. Однако отрицательный EPS и высокая волатильность требуют осторожности.
2026-04-21	—	Hold	Компания показывает значительный рост за последние месяцы, что свидетельствует о позитивной динамике. Однако отрицательный EPS и отсутствие данных о доходах указывают на определенные риски.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-08-14	Maxim Group	Target Raised	50 → 55	42.88
2026-08-13	Canaccord Genuity	Target Raised	— → 64	42.79
2026-08-13	Robert W. Baird	Target Raised	57 → 75	42.79
2026-08-12	RBC Capital	Update	— → 66	42.79
2026-08-12	Needham	Target Raised	50 → 66	42.79
2026-08-12	Oppenheimer	Target Raised	60 → 70	43.05
2026-07-27	Wells Fargo	Update	— → 68	43.17
2026-07-24	Piper Sandler	Target Raised	48 → 73	42.93
2026-07-08	Stifel Nicolaus	Target Raised	30 → 60	44.48
2026-06-30	Canaccord Genuity	Target Lowered	60 → 58	46.55
2026-06-23	Needham	Target Raised	— → 50	36.67
2026-06-22	Canaccord Genuity	Target Raised	38 → 60	38.1088
2026-06-22	Oppenheimer	Target Raised	40 → 60	37.95
2026-06-22	Leerink Partners	Target Raised	— → 52	37.91
2026-05-08	Piper Sandler	Target Lowered	49 → 48	23.2
2026-04-23	Oppenheimer	Target Raised	25 → 40	22.925
2026-04-16	Stifel Nicolaus	Update	— → 30	22.46
2026-04-16	Canaccord Genuity	Target Raised	25 → 38	22.15
2026-04-10	Piper Sandler	Update	— → 49	21.5502
2026-02-23	Wolfe Research	Update	— → 25	16.95
2026-01-29	Jefferies	Update	— → 30	17.24
2026-01-29	Robert W. Baird	Target Raised	16 → 37	16.84
2026-01-23	RBC Capital	Target Raised	20 → 36	17.4
2025-10-13	Needham	Update	— → 28	11.81

News Page 1 of 1

Nothing yet